Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancer
Pippa Scott2026-08-27T16:25:49+00:00Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting




